ASCO GU 2020 Prostate Cancer - Results from #40

Viewing 41-60 of 92 articles

ASCO GU 2020: Apalutamide for mCSPC in TITAN: Outcomes in Patients with Low- and High-Risk Disease

ASCO GU 2020: Treatment Selection in mHSPC: Considerations Now and Downstream in an Evolving Therapeutic Landscape

ASCO GU 2020: Contemporary Clinical Impact of Genetic and Genomic Testing in Prostate Cancer

ASCO GU 2020: Long Term Follow-Up from a Phase III Randomized Trial of Conventional vs Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CRUK/06/016): Update from the CHHiP Trial

ASCO GU 2020: KEYNOTE-365 Cohort A Updated Results: Pembrolizumab Plus Olaparib in Docetaxel-Pretreated Patients with mCRPC

ASCO GU 2020: Pain Response and Health-Related Quality of Life Analysis in Patients with Metastatic Castration-Resistant Prostate Cancer (CARD)

ASCO GU 2020: Abiraterone Acetate with or without Cabazitaxel in the Treatment of Chemotherapy Naive Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: Challenging Cases in Prostate Cancer – Case 3: Genomic Biomarkers

ASCO GU 2020: Challenging Cases in Prostate Cancer – Case 2: M1b Hormone-Sensitive Prostate Cancer with Low Metastatic Burden

ASCO GU 2020: Challenging Cases in Prostate Cancer – Case 1: PSMA PET/CT Imaging

ASCO GU 2020: Circulating Tumor DNA (ctDNA) to Detect Neuroendocrine Prostate Cancer Genomic and DNA Methylation Changes

ASCO GU 2020: Luminal B Subtype as a Predictive Biomarker of Docetaxel Benefit for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Correlative Study of E3805 CHAARTED

ASCO GU 2020: PROfound: Efficacy of Olaparib by Prior Taxane Use in Patients with mCRPC and Homologous Recombination Repair Gene Alterations

ASCO GU 2020: Optimal Integration of Systemic and Localized Treatment for High-Risk Localized Prostate Cancer - From the Perspective of a Surgeon

ASCO GU 2020: Next-Generation Sequencing (NGS) of Tumor Tissue from >4000 Men with mCRPC: The PROfound Phase III Study Experience

ASCO GU 2020: Best of the Journals in Prostate Cancer - Radiation Oncology Perspective

ASCO GU 2020: Best of the Journals in Prostate Cancer - Medical Oncology Perspective

ASCO GU 2020: Best of the Journals in Prostate Cancer - Surgical Perspective

ASCO GU 2020: Comparative Quality of Life in Patients Randomized Contemporaneously to Docetaxel or Abiraterone In the STAMPEDE Trial

ASCO GU 2020: Update from the CHHiP Trial: Eight-Year Outcomes of a Phase III Randomized Trial of Conventional Versus Hypofractionated High-Dose Intensity Modulated Radiotherapy For Prostate Cancer

1
2
3
4
5